Mitragynine: Pharmacology, Human Evidence, Safety & 2026 Research Status

Important safety notice
This page is an educational evidence review, not medical advice, a dosing guide, a sourcing guide, or a recommendation to use kratom or isolated mitragynine. Kratom and mitragynine are not FDA-approved treatments. Repeated exposure can be associated with tolerance, dependence, and withdrawal, and serious adverse events have been reported, particularly with concentrated products and polydrug exposure.

---

Quick answers

For the broader dependence, withdrawal, harm-reduction, and emerging-alkaloid evidence cluster, see the Substance Use Evidence Hub.

---

Bottom line

Mitragynine is the major indole alkaloid in kratom (Mitragyna speciosa), and it has real opioid-receptor activity — but the human evidence is much thinner than the online marketing around kratom often suggests.

The evidence picture changed materially during 2026:

• NIH reported that an FDA-cleared Investigational New Drug (IND) for a purified mitragynine formulation had taken effect, clearing the way for a Phase I human safety study investigating mitragynine as a potential treatment for opioid use disorder. An IND is authorization to investigate a drug; it is not FDA approval or proof of efficacy.
• A 2026 controlled pharmacokinetic study added the first published human PK data for a concentrated kratom extract, extending earlier leaf-powder and tea studies.
• A separate 2026 analytical study validated simultaneous measurement of 12 kratom alkaloids and five mitragynine metabolites in human plasma, including 7-hydroxymitragynine and mitragynine pseudoindoxyl.
• A 2026 human-receptor study further characterized mitragynine and other kratom alkaloids at human mu-, kappa-, and delta-opioid receptors.
• A 2026 systematic review found that pain evidence remains predominantly preclinical and that human efficacy evidence is limited and inconsistent.
• Federal regulatory attention in 2026 has focused heavily on enhanced 7-OH and synthetic related compounds, not on treating ordinary mitragynine research as an established medicine.

The right takeaway is neither “mitragynine is harmless” nor “mitragynine is simply morphine.” It is a pharmacologically active alkaloid with a distinctive and incompletely understood human risk/benefit profile.

---

Evidence snapshot

---

What is mitragynine?

Mitragynine is a corynanthe-type indole alkaloid and the most abundant major alkaloid in many kratom preparations. It occurs naturally in Mitragyna speciosa, a tree native to Southeast Asia.

Kratom is not a single-compound drug. Leaf and extracts contain a mixture of alkaloids, including mitragynine, speciociliatine, speciogynine, paynantheine, corynantheidine, 7-hydroxymitragynine and numerous minor constituents. Composition varies with plant material, preparation, extraction, processing, and analytical method.

That distinction matters whenever a study of isolated mitragynine is used to make a claim about whole-leaf kratom — or vice versa.

---

Mitragynine vs. kratom vs. 7-OH

These terms are often blurred together online, but they describe different exposure categories.

This separation is especially important when reading headlines, adverse-event reports, receptor studies, or regulatory notices: compound identity, formulation, and product composition determine what can legitimately be inferred.

---

Pharmacology

Mitragynine has measurable activity at the mu-opioid receptor (MOR) and interacts with additional opioid and non-opioid targets. Experimental studies generally characterize it as a relatively weak or partial MOR agonist compared with classical full opioid agonists, while also showing activity at kappa and delta opioid receptors and other receptor systems.

A 2026 study using human opioid receptors expanded the evidence base by combining radioligand binding, cAMP assays, beta-arrestin recruitment, G-protein signaling, and molecular docking. The study found substantial pharmacological diversity across kratom alkaloids, including mitragynine and 7-OH. These results are valuable for mechanism, but they are not human clinical outcome studies.

About “biased signaling”

Mitragynine and related kratom alkaloids are often described online as “safer opioids” because some experiments show relatively limited beta-arrestin-2 recruitment.

That wording is too strong.

Signaling bias is a receptor-level pharmacology finding. It does not by itself prove that a compound cannot cause respiratory depression, dependence, withdrawal, sedation, or other opioid-related harms in humans. Current research is better described as mechanistically interesting but clinically incomplete.

---

Pharmacokinetics: the 2026 update

Human PK data have progressed from very small tea/leaf studies to controlled extract work.

Dried leaf powder

A 2024 randomized, double-blind, placebo-controlled study evaluated 500–4,000 mg of dried kratom leaf powder containing approximately 6.65–53.2 mg mitragynine. Median mitragynine Tmax was approximately 1.0–1.3 hours after single doses, steady state was approached after repeated daily administration, and the highest mean mitragynine half-life was approximately 43 hours after a single dose and about 68 hours after repeated dosing.

7-OH was measurable after oral leaf administration even when it was not present in the administered product at a comparable level, supporting in-human metabolic formation from mitragynine.

Concentrated kratom extract

A 2026 randomized, double-blind, placebo-controlled study extended PK work to a concentrated dried kratom extract containing 39.5% mitragynine. The study characterized single and repeated exposure and found dose-dependent increases in mitragynine and 7-OH plasma concentrations.

This is an important upgrade in the evidence base because extract PK cannot simply be assumed to equal leaf-powder PK.

It still does not establish a therapeutic dose, an appropriate consumer dose, or long-term safety.

CYP3A4 and 7-OH formation

Human work supports CYP3A4-mediated conversion of mitragynine to 7-hydroxymitragynine. In a controlled interaction study, itraconazole pretreatment reduced 7-OH exposure while increasing mitragynine exposure, providing direct human evidence that CYP3A4 participates in the metabolic pathway.

This is clinically important because enzyme inhibition or induction, liver function, genetics, product composition, and co-administered drugs can change exposure.

Important: this section describes pharmacokinetics and interaction evidence. It is not a recommendation to manipulate metabolism or combine products.

---

Mitragynine → 7-hydroxymitragynine → other metabolites

The parent compound does not tell the entire pharmacological story.

Mitragynine can be metabolized to 7-hydroxymitragynine (7-OH), a more potent MOR-active metabolite. Additional metabolites include mitragynine 16-carboxylic acid and 9-hydroxycorynantheidine, among others.

A 2026 validated plasma method simultaneously measured 17 analytes — 12 kratom alkaloids plus five mitragynine metabolites — in human plasma. The study reinforces an important analytical point: human exposure is a multi-analyte problem, not simply “how much mitragynine was in the product?”

Mitragynine pseudoindoxyl is also relevant to the broader metabolic discussion, but evidence about its formation, stability, and contribution to human effects should not be used to imply that ordinary kratom leaf is equivalent to commercial pseudoindoxyl products.

---

Human studies: what we actually know

Acute mitragynine study

A controlled exploratory human study examined single mitragynine exposures in healthy adults and assessed subjective effects, neurocognition, vital signs, and pain tolerance. Most measured outcomes were not substantially changed, although some low-exposure findings included changes in arousal/attention measures.

The sample was small and the study was not designed to establish therapeutic efficacy or long-term safety.

NIH Phase I research milestone

In June 2026, NIH announced that an FDA-cleared IND for a purified mitragynine formulation had taken effect, allowing an NIH-led Phase I clinical trial to investigate mitragynine as a potential treatment for opioid use disorder.

This is a major research milestone because it moves purified mitragynine further into formal human drug development.

It does not mean:

• mitragynine is an approved treatment;
• mitragynine has been proven effective for opioid use disorder;
• a commercial kratom product is equivalent to the investigational formulation;
• people should self-treat opioid use disorder with kratom or mitragynine.

That evidence boundary is worth keeping very clear.

---

Pain evidence: promising mechanism, insufficient clinical proof

Preclinical studies repeatedly show antinociceptive effects from kratom and mitragynine in animal models.

A 2026 systematic review covering 44 studies — 28 preclinical and 16 human — concluded that the preclinical signal is substantially stronger than the human clinical evidence. Human studies remain small and are often focused on experimental pain in healthy volunteers rather than patients with chronic pain.

Current conclusion: mitragynine/kratom has a credible pharmacological basis for analgesic research, but there is not enough human evidence to claim established clinical efficacy for pain.

---

Dependence and withdrawal

Repeated kratom exposure can produce tolerance, physical dependence, and withdrawal. The clinical presentation can overlap with opioid withdrawal, although severity and symptom patterns vary between people and products.

Risk is affected by factors such as:

• duration and frequency of exposure;
• product concentration and consistency;
• individual metabolism;
• co-use with other psychoactive substances;
• whether the product contains elevated 7-OH or other potent derivatives.

The evidence does not support a single universal withdrawal timeline or a reliable conversion between kratom, mitragynine, 7-OH, and prescription opioids.

For severe withdrawal, intoxication, breathing problems, confusion, seizures, or inability to stay awake, professional medical assessment is more appropriate than copying an internet taper.

---

Safety and toxicology

Respiratory effects

Mitragynine generally produces less respiratory depression than classical full MOR agonists in several experimental models, but “less” is not equivalent to “none.” Risk can change with dose, formulation, 7-OH exposure, and especially co-use with other central nervous system depressants.

The strongest respiratory-depression evidence for the current kratom-related product market increasingly concerns concentrated 7-OH and potent synthetic derivatives, which should not be treated as interchangeable with ordinary mitragynine-dominant leaf.

Liver injury

Kratom-associated liver injury has been reported, usually as an uncommon but potentially serious adverse event. Causality is complicated by product variability, co-medications, contaminants, and individual susceptibility.

Cardiovascular and neurologic effects

Published case reports and surveillance literature have described cardiovascular and neurologic adverse events, including seizures. Again, causality is often difficult to establish from polysubstance and poorly characterized product exposures.

Polydrug exposure

One of the most important real-world risk multipliers is combining kratom-related alkaloids with other substances, particularly opioids, benzodiazepines, alcohol, sedatives, or other CNS-active drugs.

A lower-risk profile in one controlled experiment should never be interpreted as protection against a dangerous combination.

---

Drug interactions and metabolism

Mitragynine has shown clinically relevant and in-vitro effects involving cytochrome P450 enzymes, including CYP3A4 metabolism and CYP2D6 inhibition signals.

Potential consequences include altered exposure to mitragynine itself, altered 7-OH formation, and changes in exposure to other medicines metabolized by affected pathways.

Because interaction evidence comes from a mix of human studies, microsomal experiments, and modeling, the magnitude of a particular interaction cannot be predicted reliably from enzyme tables alone.

Practical evidence rule: if a medication has a narrow therapeutic index or significant CNS effects, product-specific and patient-specific interaction risk deserves professional review.

---

Traditional leaf vs. extracts vs. enhanced 7-OH products

These should be treated as separate evidence categories.

This distinction is central to responsible interpretation of the literature.

---

2026 federal regulatory snapshot

The federal regulatory story around kratom-related compounds is changing quickly.

In July 2026, DEA announced Notices of Intent concerning 7-hydroxymitragynine above a specified threshold and three related synthetic compounds: mitragynine pseudoindoxyl, MGM-15, and MGM-16.

That action is important for understanding the emerging market for concentrated 7-OH and synthetic derivatives, but it should not be paraphrased as “mitragynine was federally scheduled in July 2026.” The substances and thresholds in the notices matter.

At the same time, NIH's June 2026 IND announcement shows the opposite side of the research landscape: purified mitragynine is being investigated in a controlled clinical-development pathway.

Those facts can coexist:

Research authorization is not marketing approval, and regulatory scrutiny of related compounds is not proof that every mitragynine exposure is pharmacologically or legally identical.

State and local laws can be stricter and can change independently. This page is not legal advice.

---

Research gaps

The biggest unanswered questions include:

• long-term safety of repeated purified mitragynine exposure;
• clinical efficacy for opioid use disorder and other proposed indications;
• how purified mitragynine compares with whole-leaf and standardized extract exposures;
• the clinical importance of 7-OH and other metabolites at ordinary exposure levels;
• individual differences in CYP-mediated metabolism;
• clinically meaningful drug-drug interactions;
• long-term dependence trajectories and predictors of problematic use;
• how product adulteration and labeling variability affect real-world risk.

---

FAQ

Is mitragynine the same as kratom?
No. Mitragynine is one major alkaloid in kratom. Whole-leaf kratom contains many additional constituents.

Is mitragynine an opioid?
It is an alkaloid with opioid-receptor activity, especially at the mu-opioid receptor. Its pharmacology differs from classical full opioid agonists, but that does not make it non-opioid or risk-free.

Does mitragynine turn into 7-OH in humans?
Yes. Human pharmacokinetic studies support metabolic formation of 7-hydroxymitragynine from mitragynine, with CYP3A4 playing an important role.

Is mitragynine FDA-approved?
No. The 2026 NIH IND is authorization to investigate a purified formulation in a clinical trial; it is not FDA marketing approval.

Does the NIH trial prove mitragynine treats opioid use disorder?
No. A Phase I study is primarily an early clinical-development step. Efficacy and appropriate clinical use require later evidence.

Is mitragynine the same as concentrated 7-OH?
No. Mitragynine is the parent alkaloid; 7-OH is a more potent opioid-active metabolite that can also be present at enhanced levels in commercial products.

Does reduced beta-arrestin recruitment make mitragynine safe?
No. Signaling bias is an experimental pharmacology finding, not a guarantee against respiratory depression, dependence, withdrawal, or other adverse effects.

Is there a proven consumer dose of mitragynine?
This page does not provide a consumer dosing recommendation. Human studies have used defined research exposures, but those results do not establish a generally safe or effective dose for self-treatment.

---

Related evidence reviews

• Substance Use Evidence Hub: dependence, withdrawal, harm reduction & emerging compounds
• 7-Hydroxymitragynine: pharmacology, dependence, product testing & legal status
• Mitragynine pseudoindoxyl: pharmacology, product market & federal status
• MGM-15 / dihydro-7-hydroxymitragynine evidence review
• Corynoxine B opioid and addiction evidence review
• 7-OH withdrawal evidence review

---

Educational and research purposes only. This page does not provide medical, legal, dosing, sourcing, or withdrawal-treatment advice.